Insight Brief
How Patients Are Accessing GLP-1s Through Alternative Channels
This Insight Brief is part of an ongoing series on A Brave New World: Therapeutic Deep Dives.
Jeff Thiesen, Managing Principal, U.S. Advisory and Brand Intelligence, Market Access Consulting, IQVIA
Aug 21, 2025

Glucagon-like-peptide-1 agonists ("GLP-1s") are an important growth driver for the biopharmaceutical industry both in terms of sales and demand. They have made headlines over the past several months as shortages, compounding, telehealth partnerships, and policy impact the diabetes and weight loss markets. In a recent webinar, IQVIA shared insights on the latest trends, the role of pharmacy compounding and telehealth, and key considerations for the next three to five years. This information is summarized for you in the Insights Brief - How Patients Are Accessing GLP-1s Through Alternative Channels.

Download now for more detail.

Related solutions

Contact Us